Scientists Urge Caution on Some Experimental Parkinson’s Therapies

Some experimental treatments for Parkinson’s disease that are meant to help brain cells may actually be doing more harm than good, according to new research. The therapies in question are designed to improve the function of mitochondria — the tiny “powerhouses” inside cells that generate energy. Since problems with mitochondria are a well-known feature of Parkinson’s, boosting their health has long been seen as a promising approach. One popular idea is to enhance mitophagy, the cell’s natural process of cleaning out damaged mitochondria. This process is mainly governed by two genes, PINK1 and PARKIN. The new study tested two experimental compounds, MTK458 and FB231. Both were created to activate the PINK1/PARKIN pathway, with the hope of stimulating mitophagy and helping cells stay healthy. In the first round of lab tests, the results looked encouraging. When healthy cells were treated with toxins that damage mitochondria, adding the new compounds boosted mitophagy. In fact, when the two drugs were combined, the effect was especially strong. But when the researchers dug deeper, the story changed. They discovered that the compounds weren’t directly switching on the genes as intended. Instead, they were acting like weak mitochondrial toxins themselves, creating a small amount of damage. In other words, the drugs were essentially stressing the mitochondria, which then forced cells to clean them up. One of the study’s authors explained it with a vivid image: imagine your microwave is broken. Instead of calling the garbage collector to pick it up, you smash it further with a sledgehammer. That would certainly force you to throw it out, but it’s hardly the right solution. The findings highlight the need for extreme care when developing Parkinson’s therapies. A drug may look like it’s helping in lab tests, but it might only appear effective because it’s damaging the very thing it’s supposed to protect. The researchers concluded that future studies will need to carefully rule out the possibility that promising compounds are, in fact, acting as toxins. This kind of basic science is crucial, they stressed, because billions of dollars go into drug development, and understanding exactly how a treatment works could save time, money, and — most importantly — protect people from harmful outcomes.